Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and response

Objectives: The aim of this study was to identify clinical predictors of treatment attrition, medication choice, improvement and response to pharmacotherapy in adult attention-deficit/hyperactivity disorder (ADHD). Methods: 150 ADHD patients were enrolled and naturalistically followed-up for at least 4 months. Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) were used to measure ADHD severity. Results: 58 subjects (38.7%) were lost at follow-up, while 75 (50%) completed follow-up assessment, on average after 26.05 ± 11.99 weeks; 35 were treated with atomoxetine (ATX) and 40 with methylphenidate (MPH). Treatments were moderately effective (d = 0.72) and 37 patients (49.3%) were responders (≥30% CAARS-O:SV decrease). Patients lost at follow-up had lower inattentive symptoms, less generalized anxiety and family history of bipolar disorder, more amphetamine use disorder than follow-up completers. Compared to ATX-treated subjects, MPH-treated patients had greater severity of hyperactivity/impulsivity and were more frequently diagnosed with alcohol use disorder. While MPH and ATX showed similar efficacy, more pronounced improvements were observed in patients with combined ADHD, anxiety and substance use disorders. ADHD severity and comorbid substance use positively predicted response. Conclusions: Consensus-based hierarchical treatment of ADHD comorbidity is not consistently supported. Comorbid anxiety, mood and substance use disorders should not discourage the treatment of adult ADHD.

[1]  A. Iwanami,et al.  Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder , 2022, Neuropsychopharmacology reports.

[2]  R. Jaeschke,et al.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review , 2021, Psychopharmacology.

[3]  G. Perugi,et al.  Development of bipolar disorder in patients with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis of prospective studies. , 2021, Journal of affective disorders.

[4]  U. Werneke,et al.  Suicidal and non-suicidal self-injurious behaviour in patients with bipolar disorder and comorbid attention deficit hyperactivity disorder after initiation of central stimulant treatment: a mirror-image study based on the LiSIE retrospective cohort , 2020, Therapeutic advances in psychopharmacology.

[5]  Ike C de la Peña,et al.  Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Subtype/Presentation: Research Progress and Translational Studies , 2020, Brain sciences.

[6]  A. Aysev,et al.  An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School? , 2020, Journal of attention disorders.

[7]  G. Perugi,et al.  Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD) , 2018, Expert opinion on pharmacotherapy.

[8]  E Sobanski,et al.  Updated European Consensus Statement on diagnosis and treatment of adult ADHD , 2018, European Psychiatry.

[9]  M. Pavlicova,et al.  How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. , 2018, Drug and alcohol dependence.

[10]  S. Cortese,et al.  Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis , 2018, Neuroscience & Biobehavioral Reviews.

[11]  Kenneth K C Man,et al.  Association of Risk of Suicide Attempts With Methylphenidate Treatment , 2017, JAMA psychiatry.

[12]  J. Halperin,et al.  Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. , 2017, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  J. Oosterlaan,et al.  Childhood Psychiatric Disorders as Risk Factor for Subsequent Substance Abuse: A Meta-Analysis. , 2017, Journal of the American Academy of Child and Adolescent Psychiatry.

[14]  M. Thase,et al.  The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. , 2017, The American journal of psychiatry.

[15]  W. Pelham,et al.  Differential Response to Methylphenidate in Inattentive and Combined Subtype ADHD , 2017, Journal of attention disorders.

[16]  Tom V. Hanley,et al.  Childhood Factors Affecting Persistence and Desistence of Attention-Deficit/Hyperactivity Disorder Symptoms in Adulthood: Results From the MTA. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  James G. Scott,et al.  Long-Term Outcomes of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder: A Systematic Review and Meta-Analysis. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  D. Coghill,et al.  Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database , 2016, CNS Drugs.

[19]  C. Kieling,et al.  Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis , 2016, European Child & Adolescent Psychiatry.

[20]  V. Reed,et al.  A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients , 2016, Journal of psychopharmacology.

[21]  R. Findling,et al.  Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials , 2016, CNS neuroscience & therapeutics.

[22]  S. Leppämäki,et al.  Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine , 2015, European Psychiatry.

[23]  Mark Olfson,et al.  Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder , 2007, Journal of managed care pharmacy : JMCP.

[24]  J. Buitelaar,et al.  The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research , 2015, CNS Drugs.

[25]  C. Viswesvaran,et al.  The co-occurrence of attention-deficit/hyperactivity disorder and unipolar depression in children and adolescents: a meta-analytic review. , 2014, Clinical psychology review.

[26]  J. Haavik,et al.  Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity , 2014, European Neuropsychopharmacology.

[27]  W. Retz,et al.  Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD) , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[28]  Linda Chang,et al.  Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. , 2014, Addiction.

[29]  P. Asherson,et al.  Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials , 2014, Journal of psychopharmacology.

[30]  C. Ose,et al.  Treatment adherence and persistence in adult ADHD: Results from a twenty-four week controlled clinical trial with extended release methylphenidate , 2014, European Psychiatry.

[31]  J. Franck,et al.  Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial , 2013, Addiction.

[32]  B. Franke,et al.  Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder , 2013, British Journal of Psychiatry.

[33]  A. Palmini,et al.  A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH) , 2013, Journal of attention disorders.

[34]  S. Walsh,et al.  Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial. , 2013, Drug and alcohol dependence.

[35]  S. Faraone,et al.  Examining the comorbidity between attention deficit hyperactivity disorder and bipolar I disorder: a meta-analysis of family genetic studies. , 2012, The American journal of psychiatry.

[36]  P. Chokka,et al.  Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. , 2012, Current drug abuse reviews.

[37]  L. Marangell,et al.  COMPREHENSIVE REVIEW OF FACTORS IMPLICATED IN THE HETEROGENEITY OF RESPONSE IN DEPRESSION , 2012, Depression and anxiety.

[38]  C. Violato,et al.  Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study , 2011, Attention deficit and hyperactivity disorders.

[39]  Natalia del Campo,et al.  The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/Hyperactivity Disorder , 2011, Biological Psychiatry.

[40]  J. Buitelaar,et al.  Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  Robert E. Strong,et al.  Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine , 2011, Attention deficit and hyperactivity disorders.

[42]  P. Wender,et al.  A One Year Trial of Methylphenidate in the Treatment of ADHD , 2011, Journal of attention disorders.

[43]  P. Chokka,et al.  Adult ADHD and its comorbidities, with a focus on bipolar disorder. , 2010, Journal of affective disorders.

[44]  A. Gabriel.  The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study , 2010, Attention deficit and hyperactivity disorders.

[45]  K. Chang,et al.  Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. , 2009, Journal of child and adolescent psychopharmacology.

[46]  J. McGough,et al.  Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD , 2009, Journal of attention disorders.

[47]  William Kronenberger,et al.  Atomoxetine treatment in adults with attention‐deficit/hyperactivity disorder and comorbid social anxiety disorder , 2009, Depression and anxiety.

[48]  Rodney J. Moore,et al.  Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. , 2008, Drug and alcohol dependence.

[49]  Rodney J. Moore,et al.  Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD , 2008, Journal of attention disorders.

[50]  R. Pihl,et al.  Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users , 2007, Human psychopharmacology.

[51]  J. Johnston,et al.  Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. , 2006, Journal of managed care pharmacy : JMCP.

[52]  Poonam Soni,et al.  Emotional Dysregulation in Adult ADHD and Response to Atomoxetine , 2005, Biological Psychiatry.

[53]  A. Perwien,et al.  Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder , 2004, Journal of managed care pharmacy : JMCP.

[54]  R. McIntyre,et al.  Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. , 2018, Research in developmental disabilities.

[55]  Liang-Jen Wang,et al.  Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan. , 2016, Journal of psychiatric research.

[56]  R. Barkley.  Sluggish Cognitive Tempo (Concentration Deficit Disorder?): Current Status, Future Directions, and a Plea to Change the Name , 2013, Journal of Abnormal Child Psychology.

[57]  J. Kooij,et al.  Adult ADHD , 2013, Springer London.

[58]  C. Ose,et al.  A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder , 2008, European Archives of Psychiatry and Clinical Neuroscience.